Best of the Blog: IN VIVO, January 2009
Executive Summary
Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In January, Windhover's editorial staff posted 48 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights included our ongoing coverage of Pfizer's acquisition of Wyeth as well as dispatches from the JP Morgan meeting in San Francisco. And we awarded IN VIVO Blog's Deal of the Year. Here are a few of our favorite blog posts and excerpts for stories not covered elsewhere in this month's IN VIVO.
You may also be interested in...
GSK Tries to Mimic Real-World Biotech
Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.